Skip to content
10-K

Annual Report

ATOSSA THERAPEUTICS, INC. ATOS

0001193125-26-124396

← back to feed
Filed
Mar 25, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 17, 2026 8.61M sh
Shares Diluted FY 2025 · Dec 31, 2025 8.61M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 8.39M sh
Capex FY 2025 · Dec 31, 2025 $23K
Capex FY 2025 · Dec 31, 2024 $19K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$29.76M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$21.03M
Cash And Equivalents FY 2025 · Dec 31, 2025 $41.3M
Cash And Equivalents FY 2025 · Dec 31, 2024 $71.08M
Stockholders Equity FY 2025 · Dec 31, 2025 $39.35M
Stockholders Equity FY 2025 · Dec 31, 2024 $71.48M
Stockholders Equity FY 2025 · Dec 31, 2023 $91.02M
Current Liabilities FY 2025 · Dec 31, 2025 $8.26M
Current Liabilities FY 2025 · Dec 31, 2024 $4.97M
Total Liabilities FY 2025 · Dec 31, 2025 $8.26M
Total Liabilities FY 2025 · Dec 31, 2024 $4.97M
Current Assets FY 2025 · Dec 31, 2025 $45.62M
Current Assets FY 2025 · Dec 31, 2024 $74.46M
Total Assets FY 2025 · Dec 31, 2025 $47.61M
Total Assets FY 2025 · Dec 31, 2024 $76.44M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.04
Eps Diluted restated FY 2025 · Dec 31, 2024 −$3.04
Eps Basic FY 2025 · Dec 31, 2025 −$4.04
Eps Basic restated FY 2025 · Dec 31, 2024 −$3.04
Sga Expense FY 2025 · Dec 31, 2025 $15.96M
Sga Expense FY 2025 · Dec 31, 2024 $13.5M
Rd Expense FY 2025 · Dec 31, 2025 $21.19M
Rd Expense FY 2025 · Dec 31, 2024 $14.12M
Net Income FY 2025 · Dec 31, 2025 −$34.77M
Net Income FY 2025 · Dec 31, 2024 −$25.5M
Operating Income FY 2025 · Dec 31, 2025 −$37.14M
Operating Income FY 2025 · Dec 31, 2024 −$27.62M